While the slope of decline in FEV 1 has traditionally been calculated from the post-rather than the pre-bronchodilator measurement in COPD interventional trials, it is not clear whether and to what extent these two slopes differ in symptomatic patients with COPD. Therefore, we used data from the 4-year UPLIFT trial of tiotropium 18 mcg QD vs. placebo to compare annual rates of change in pre-vs. post-bronchodilator FEV 1 in 5041 patients with moderate to very severe COPD (mean FEV 1 48% pred) in whom the post-bronchodilator FEV 1 was measured after 4 inhalations of two different classes of short-acting inhaled bronchodilators at baseline and 1 month and every 6 months post-randomization over 4 years. Linear mixed effects models were used to estimate annual rates of decline in FEV 1 and FVC pre-and post-bronchodilator in each treatment group separately, after adjusting for height, gender, smoking status, baseline % predicted FEV 1 or FVC, and baseline acute % improvement in lung function. The slopes of the post-bronchodilator FEV 1 and FVC were significantly steeper than the pre-bronchodilator slopes regardless of treatment arm (p < 0.001), while the estimated variances of the slopes were similar. Post-bronchodilator increases in FEV 1 and FVC diminished progressively and significantly (p < 0.0001) over the 4-year trial, suggesting a possible explanation for the significant differences between the pre-and post-bronchodilator slopes. While the reasons for these differences are not completely clear, they are important to consider when assessing treatment effects on rates of decline in FEV 1 and FVC. ª
Introduction
For nearly 50 years the rate of progression of COPD has been defined by the slope of the annual decline in FEV 1 determined from serial measurements of FEV 1 obtained over a span of years in the course of observational or intervention studies. In intervention trials conducted over the last few decades, this slope has been determined mainly from serial measurements of the post-, rather than the pre-, bronchodilator FEV 1 [1e10] . The rationale for the latter practice appears to derive from the assumption that there may be less variability in the post-than the pre-bronchodilator measurement and that the post-bronchodilator value would be less influenced by noncompliance with instructions to withhold bronchodilator medication during the washout period prior to scheduled spirometric testing. However, we recently reported that the slope estimates over 5 years, as well as the standard errors of these estimates, were only slightly higher for the pre-than post-bronchodilator FEV 1 in 4484 Lung Health Study (LHS) participants with mild to moderate airflow obstruction (mean FEV 1 78% predicted) [1] . These findings suggested that serial pre-bronchodilator FEV 1 measurements may be sufficient for comparing the impact of interventions on the annual rates of change in FEV 1 . On the other hand, the postbronchodilator measurements in the LHS were obtained only approximately15 min after only 2 inhalations of a shortacting beta-agonist, suggesting that the FEV 1 response was submaximal. Moreover, results could possibly differ in a more severe COPD population. In order to investigate the latter possibility, we analyzed FEV 1 and FVC measured before and 30e90 min after near-maximal doses of two different bronchodilators at baseline and every 6 months over 4 years in a population of patients with more advanced, moderate to very severe COPD (mean FEV 1 48% predicted) who were participants in the Understanding Potential Long-term Impacts on Function with Tiotropium (UPLIFT) trial of tiotropium 18 mcg Handihaler once daily vs. placebo [9] .
Methods
In a post-hoc analysis using data from the UPLIFT trial, we compared annual rates of change in pre-vs. post-bronchodilator FEV 1 in 5041 patients with moderate to very severe COPD (mean FEV 1 48% predicted) in whom the postbronchodilator FEV 1 was measured at the time of expected peak action of 4 inhalations of two different classes of short-acting inhaled bronchodilators (ipratropium, 18 mg/ inhalation, followed 1 h later by albuterol, 100 mg/inhalation, followed 30 min later by spirometry) at baseline and 1 month and every 6 months post-randomization over 4 years.
Analytic methods
Annual rates of change were estimated for the two treatment groups (tiotropium and placebo) separately. Among the 5992 subjects in the original study, the 5041 (84.1%) who had at least 3 serial measurements beginning with the measurement at 6 months were included in this analysis. Baseline characteristics of patients in each group are summarized using descriptive statistics. Comparison of treatment groups was performed using t-tests for normallydistributed continuous data, the Wilcoxon rank-sum test for non-normal continuous variables, and the Chi-square test for categorical variables. Linear mixed effects models were used to estimate annual change in FEV 1 and FVC (ml/yr) measured pre-and post-bronchodilator for each group separately. The model assumed random intercept and random slope to take into account between-subject heterogeneity and estimated the slope (annual decline) using data from 6 months on (rather than from baseline) up to year 4 to exclude the bump-up in lung function that was observed between baseline and the 6-month visit in both treatment groups. The analysis was also adjusted for height, gender, smoking, baseline % predicted FEV 1 (or FVC), and baseline acute % improvement after bronchodilator administration. Smoking status was categorized as continuing smoking at all visits (n Z 629, 12.5%), sustained ex-smoking at all visits (n Z 2972, 59.0%) and intermittent smoking (n Z 1440, 28.6%). Separate analyses were also performed according to GOLD grades of severity of airflow obstruction IeII, III and IV. All analyses were performed using SAS software v9.2 (Cary, NC).
Written informed consent was obtained from all participants enrolled in the UPLIFT trial. The study was approved by the institutional review boards of each of the participating centers and was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. The study was registered with ClinicalTrials.gov (number NCT00144339).
Results
Of the 5992 subjects enrolled in the UPLIFT trial, 5041 (84.1%) fulfilled criteria for inclusion in the present analysis. The baseline characteristics of these were similar to those of the entire UPLIFT study population [9] and are shown in Table 1 . Approximately three-fourths of the participants were male, >90% were Caucasian and their mean age was w64 years. Average FEV 1 was w40% % predicted pre-and w48% predicted post-bronchodilator administration. Fortyeight percent of the subjects had mild-moderate airflow obstruction (GOLD grade IeII), 43% severe airflow obstruction (GOLD grade III) and 8% very severe obstruction (GOLD grade IV). Slightly less than 30% were current smokers. No differences were noted between treatment arms.
The slope estimates for the annual change in pre-and postbronchodilator FEV 1 and FVC in ml/yr obtained from the linear mixed effects model are shown in Table 2 . Slopes were adjusted for the following covariates: height, gender, smoking status (continuing smoking at all visits sustained, ex-smoking at all visits and intermittent smoking), baseline FEV 1 (or FVC) % predicted, baseline % acute improvement in response to bronchodilator administration by treatment group. The observed data for the pre-and post-bronchodilator FEV 1 and FVC for each treatment arm are also illustrated in Fig. 1 and Fig. 2 , respectively. The adjusted slope estimates are very similar to those unadjusted for the various covariates ( Table  2 ). The mean slopes determined from the post-bronchodilator FEV 1 and FVC are significantly steeper than those calculated from the pre-bronchodilator measurements (p < 0.001), the differences being numerically larger for FVC than FEV 1 ( Table 2) . Although the slope differences and their variances, in general, tend to be slightly higher in the placebo than the tiotropium treatment arm, these betweentreatment differences are not statistically significant.
Slope estimates for the annual change in pre-and postbronchodilator FEV 1 and FVC stratified by the severity of airflow obstruction (GOLD grades IeII, III and IV) are shown in Tables 3aec. For FEV 1 the pre-post bronchodilator slope differences were slightly but not significantly larger in GOLD grades III and IV compared to GOLD grades IeII. For FVC the pre-post bronchodilator slope differences were most pronounced in GOLD grades III and IV; these differences were significantly larger in GOLD III than GOLD IeII in the tiotropium arm (p Z 0.0011) and nearly significantly larger in the placebo arm (p Z 0.07). They were also significantly larger in GOLD IV than GOLD IeII in the placebo arm (p Z 0.0055) and nearly significantly larger in GOLD IV than GOLD IeII in the tiotropium arm (p Z 0.08).
Discussion
In this population of COPD patients with moderate to very severe airflow limitation participating in a 4-year trial of tiotropium vs. placebo, unlike findings from an earlier study in COPD patients with mild to moderate obstruction [1] , the slopes of the post-bronchodilator FEV 1 and FVC are significantly steeper than the slopes calculated from the prebronchodilator measurements, while the variances are similar, regardless of treatment arm ( Table 2 ). The differences between the pre-vs. post-bronchodilator slopes of decline in FEV 1 and FVC are numerically greater in GOLD grades III and IV compared to GOLD grades I and II (Table 3aec ). We hypothesized that a possible reason why the slopes determined from the post-compared to the prebronchodilator measurements might be due to reduced bronchodilator responsiveness for both FEV 1 and FVC over time. Consequently, we examined the absolute changes (milliliters) in FEV 1 and FVC at each time point over the 4-year trial beginning at month 1for each treatment arm separately (Table  4) . These data show a highly significant trend over the 4 years of the trial toward lower absolute increments in both FEV 1 and FVC in response to bronchodilator administration in each treatment group (p < 0.0001). This trend toward diminishing bronchodilator responsiveness over time could provide an explanation for the steeper post-versus pre-bronchodilator slope since it would result in relatively lower postbronchodilator values in the later compared to the earlier years of the trial, as illustrated in Fig. 3 . It might also at least partially explain the comparatively larger differences in the slopes of the pre-vs. post-bronchodilator measurements in those with GOLD grades III and IV than I-II severity of airflow obstruction (Table 3aec ) since the acute bronchodilator response (at least in terms of FEV 1 ) tends to be more robust in those with moderate compared to those with severe/very severe airflow obstruction [11, 12] . This trend toward smaller differences in the pre-vs. post-bronchodilator slopes in the UPLIFT participants with moderate airflow obstruction (average pre-bronchodilator FEV 1 49 AE 8 [SD] % predicted) might also explain the absence of any discernible differences in the pre-vs. post-bronchodilator slopes in the Lung Health Study participants, who had only mild-to-moderate airflow obstruction with a mean baseline FEV 1 of 78% predicted [2] .
Since COPD is a progressive disease characterized by an accelerated age-related decline in lung function, the degree of airflow obstruction, on average, will worsen over time. Therefore, one explanation for the diminishing bronchodilator response over the course of the UPLIFT trial could be related to the impact of the progressively worsening severity of airflow obstruction itself on the bronchodilator response. Another possible explanation could be the development of tachyphylaxis to the acute bronchodilator effect of the albuterol that was administered along with ipratropium to elicit the post-bronchodilator FEV 1 and FVC values at each measurement point. On the other hand, tolerance to the bronchodilator effect of a beta-agonist develops rapidly and appears to reach a plateau within 1e2 weeks of administration, after which it does not appear to progress further [13] . Moreover, tolerance to a beta-agonist is more evident as a decrease in the duration of action than in the peak magnitude of bronchodilation [14] . Since the post-bronchodilator FEV 1 in the UPLIFT trial was measured at the time of the peak response to the combination of albuterol and ipratropium, these findings suggest that bronchodilator tolerance does not explain the disparity in the rates of decline between the pre-versus the post-bronchodilator FEV 1 .
Whereas significant differences were noted in the pre-vs. post-bronchodilator slopes of lung function decline, the estimated variances of these slopes were similar. Therefore, no advantage accrues to post-over pre-bronchodilator spirometry with respect to reducing the variance of the slope of the FEV 1 (or FVC) in the hope of increasing statistical power to demonstrate between-treatment differences in studies comparing different interventions on the rate of progression of COPD. While the known within-and between-day variability of bronchomotor tone [15] most likely contributes to the variability of the slope of FEV 1 decline over time, bronchodilator administration has not been shown to abrogate the diurnal variability of airflow [16] . To the contrary, one might expect even greater variability in post-compared to prebronchodilator spirometry since responsiveness to bronchodilator administration has been shown to vary considerably from one session to the next [17e19]. On the other hand, prior self-administration of a bronchodilator during the washout period preceding spirometry test sessions in an intervention trial would have less of an impact on post-than prebronchodilator spirometric measurements.
It is of interest that post-hoc analyses of the results of the UPLIFT trial have revealed significant between-treatment (tiotropium vs. placebo) differences in the slope of the postbronchodilator (but not the pre-bronchodilator) rate of decline in FEV 1 in selected subgroups of trial participants, namely those with moderate airflow obstruction [20] , maintenance-naïve subjects [21] and younger individuals (<50 years of age) [22] . While the reasons for the apparently greater sensitivity of the post-compared to the prebronchodilator slope of FEV 1 decline in detecting differences in treatment responses in selected subgroups of COPD patients is unclear, these findings suggest that the postbronchodilator slope has utility in assessing treatment effects on rates of decline in lung function.
The strengths of this study include the large number of participants of varying severity in the UPLIFT trial, the relatively long follow-up period of 4 years, the use of centralized spirometry and rigorous quality control methods that resulted in high-quality measurements of FEV 1 and FVC [23] and the use of relatively large doses of two different classes of bronchodilators with the timing of post-bronchodilator spirometry to correspond to the peak magnitude of bronchodilation from each agent, so that the post-bronchodilator measurements were likely to be nearmaximal. On the other hand, the study had important limitations, particularly a high dropout rate (37% in the tiotropium arm and w45% in the placebo arm) that resulted in a large amount of missing data. While the mixed effects model assumes that the data are missing at random, it is clear that patient withdrawals were often due to worsening disease leading to missing data that cannot be assumed to be at random. Consequently, an additional analysis was performed in which the slope of decline in lung function was estimated using a joint analysis approach that models the joint distribution between the longitudinal outcome (FEV 1 or FVC) and the patient dropout time [24] (supplemental Table 1E ); this method reduces the estimated bias caused by premature discontinuations. In the joint analysis, the slopes estimated from the model adjusted for covariates are slightly higher than those estimated from the mixed effects model, but the differences between the pre-and post-bronchodilator slopes determined from the two models are similar and remain highly significant (p < 0.0001).
Another potential limitation is that some patients may not have adhered strictly to the instructions to withhold their maintenance or rescue bronchodilator therapy for the protocol-defined interval prior to spirometry testing. If this Figure 3 Estimated slopes of annual decline in pre-and postbronchodilator FEV 1 in the tiotropium (A) and placebo (B) groups derived from the mixed effects model with adjustment for covariates over 4 years (solid lines) and the acute absolute increases in FEV 1 (in ml) from the pre-bronchodilator value following bronchodilator administration at each time point except for the 1-month visit (dotted vertical arrows). The diminishing acute bronchodilator response over the 4 years of the trial appears to account for the steeper post-bronchodilator slope compared to the pre-bronchodilator slope. occurred, it could have affected the pre-bronchodilator slope without influencing the slope derived from the postbronchodilator measurements; however, unless this practice occurred systematically, it is unlikely to have affected the difference between the pre-and post-bronchodilator slopes. In summary, in a population of COPD patients with moderate to very severe airflow obstruction followed for up to 4 years as part of the UPLIFT trial of tiotropium vs. placebo, we found significant differences in the slopes of the rates of decline in FEV 1 and FVC determined from the post-vs. pre-bronchodilator measurements but no differences in the variances of these slopes. These pre-to postbronchodilator slope differences tended to be larger in patients with severe and very severe airflow obstruction compared to those with moderate impairment. No differences in these findings were noted between the tiotropium and placebo treatment groups. The absolute improvements in FEV 1 and FVC after bronchodilator administration diminished over the 4 years of the trial, providing a potential mechanism that might explain the steeper slopes determined from the post-compared to the pre-bronchodilator measurements. These slope differences need to be taken into account in studies of the impact of different interventions on the rate of decline in lung function. 
